NEW YORK (GenomeWeb News) – Millipore has acquired Oxford, UK-based BioAnaLab in a bid to expand its biopharmaceutical services offerings into the European market.

The Billerica, Mass.-based life science tools provider did not disclose the purchase price. It said that BioAnaLab's services include assay transfer and development, validation and sample analysis, pharmacokinetics and toxicokinetics, immunogenicity, biological potency, and vaccine services.

Millipore said that it would strengthen BioAnaLab's offerings with its own expertise in biomarker analytical services.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.